TSHA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
-100.0%
5.5M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
-100.0%
5.5M
0
Operating Expenses
41.9M
-11.6%
47.3M
+8.9%
43.5M
+28.7%
33.8M
-0.7%
34.0M
R&D
28.8M
-25.5%
38.6M
+14.3%
33.8M
+35.5%
25.0M
-3.1%
25.7M
SG&A
13.1M
+7.9%
12.1M
+25.5%
9.7M
+9.6%
8.8M
+6.7%
8.3M
Operating Income
-41872000
+11.6%
-47349000
-8.9%
-43486000
-53.7%
-28300000
+16.8%
-34024000
EBITDA
-41615000
+17.6%
-50491000
-16.9%
-43191000
-54.2%
-28001000
+17.0%
-33738000
Net Income
-39128000
+16.1%
-46639000
-10.0%
-42410000
-52.3%
-27851000
+14.9%
-32733000
EPS (Basic)
$-0.10
+23.1%
$-0.13
-8.3%
$-0.12
-50.0%
$-0.08
+11.1%
$-0.09
EPS (Diluted)
$-0.10
+23.1%
$-0.13
-8.3%
$-0.12
-50.0%
$-0.08
+11.1%
$-0.09
Shares (Diluted)
406.1M
+10.0%
369.0M
+0.7%
366.6M
+2.3%
358.2M
+1.4%
353.3M
Taysha Gene Therapies (TSHA) — Financials